Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[18F]-DPA-714 PET/CT in Triple Negative Breast Cancer
NCT04320030Phase 2Completed
- Sponsor
- Institut Cancérologique de l'Ouest
- Start
- Jun 2020
- Primary completion
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of DPA-714 in triple-negative breast cancer (TNBC), sponsored by Institut Cancérologique de l'Ouest. Started Jun 2020; status: completed.
02
Drugs
DPA-714
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT04320030.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04320030.